EAM
MRNS

Eventide Asset Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Eventide Asset Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,346,526
Closed -$21.2M – 175
2024
Q1 		$21.2M Sell
2,346,526
-2,183,471
-48% -$21.2M 0.33% 89
2023
Q4 		$49.2M Hold
4,529,997
– – 0.8% 44
2023
Q3 		$36.5M Buy
4,529,997
+1,356,800
+43% +$11.3M 0.66% 49
2023
Q2 		$34.5M Hold
3,173,197
– – 0.58% 56
2023
Q1 		$21.9M Buy
3,173,197
+23,197
+0.7% +$145K 0.4% 76
2022
Q4 		$12.5M Buy
+3,150,000
New +$15.5M 0.25% 99

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return